A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

Inclusion Criteria:

1. Diagnosis of CD19-positive relapsed or refractory (R/R) B-cell Non-Hodgkin'sLymphoma (NHL).

2. Must have met the following criteria for prior treatment:

3. Participants with aggressive NHL must have received at least 2 lines ofsystemic therapy (if not intended for transplant, have already undergone or beunwilling or unable to undergo chimeric antigen receptor [CAR] T-cell therapyto be eligible), or at least 3 lines of systemic therapy. Previous therapy musthave included a CD20-targeted agent and an anthracycline or alkylator.

4. Participants with follicular lymphoma (FL) must have received at least 2 linesof systemic therapy and have high-risk disease. Previous therapy must haveincluded a CD20-targeted agent and an alkylator.

5. Participants with marginal zone lymphoma (MZL) must have received at least 2prior systemic therapies.

6. Measurable disease on screening evaluations.

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

8. Adequate organ function.

9. Life expectancy of ≥12 weeks.

Exclusion Criteria:

1. Any condition that confounds the ability to interpret data from the study.

2. Central nervous system (CNS)-only involvement by malignancy. (Note: participantswith secondary CNS involvement are allowed.)

3. Prior allogeneic stem cell transplant.

4. Presence of clinically significant CNS pathology.

5. Other comorbid conditions defined in the protocol.

6. Use of prohibited medications within the washout period defined in the protocol.